Author:
Zsombor Zrubka
zsombor.zrubka@googlemail.com
Zsombor Zrubka
Sandoz Hungária Kft
Search for other papers by Zsombor Zrubka in
Current site
Google Scholar
PubMed
Search for other papers by Zsombor Zrubka in
Current site
Google Scholar
PubMed
Biologicals are the fastest growing segment of the global pharmaceutical market, reaching 199 billion USD sales per year with 9.8% 10-year compound annual growth rate (CAGR). Being less costly, yet equally efficacious and safe alternatives to originator reference products, biosimilars drive competition, promise budget savings and the opportunity for better patient-access. This paper examines the key factors and players of biosimilar competition in rheumatology in Hungary. Due to the scarcity of data, the total yearly expenditure on biologicals could only be estimated from different data sources. In 2015 the estimated expenditure on biologicals was around 100 billion HUF. In rheumatology indications the expenditure on biologicals was 10 (8.9-11.2) billion HUF, and the average annual net treatment cost was 1.2 (1.06-1.34) million HUF / per patient / year. The magnitude of societal benefits in terms of budget savings and health gains may result from the joint effort of policy makers, funders, physicians and patients. In rheumatology indications, biosimilar utilization could be increased by a policy supporting physician-driven interchange of the reference product to biosimilars. Also, creating a physician incentive system for broader use should be considered in order to realize the full economic advantages of biosimilars and contribute to sustainable healthcare financing in Hungary.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
ÁEEK (2016): Tételes Egészségügyi Adattár [National Health Database], http://tea.gyemszi.hu, accessed 29 March 2016.
-
Aitken, M. (2016): Delivering on the Potential of Biosimilar Medicines — The Role of Functioning Competitive Markets. http://www.medicinesforeurope.com/wp-content /uploads/2016/03/IMSInstitute-Biosimilar-Report-March-2016-FINAL.pdf, accessed 18 February 2016.
-
Baji, P. – Péntek, M. – Czirják, L. – Szekanecz, Z. – Nagy, G. – Gulácsi, L. – Brodszky, V. (2014a): Efficacy and Safety of Infliximab-Biosimilar Compared to Other Biological Drugs in Rheumatoid Arthritis: A Mixed Treatment Comparison. The European Journal of Health Economics 15: 53–64.
-
Baji, P. – Péntek, M. – Szántó, S. – Géher, P. – Gulácsi, L. – Balogh, O. – Brodszky, V. (2014b): Comparative Efficacy and Safety of Biosimilar Infliximab and Other Biological Treatments in Ankylosing Spondylitis: Systematic Literature Review and Meta-Analysis. The European Journal of Health Economics 15: 45–52.
-
Baji, P. – Gulácsi, L. – Lovász, B. D. – Golovics, P. A. – Brodszky, V. – Péntek, M. – Rencz, F. – Lakatos, P. L. (2016): Treatment Preferences of Originator versus Biosimilar Drugs in Crohn’s Disease; Discrete Choice Experiment among Gastroenterologists. Scandinavian Journal of Gastroenterology 51: 22–27.
-
Boncz, I. (2006): Prevention of Cervical Cancer in Low-Resource Settings. JAMA 295. 1248; author reply 1249.
-
Boncz, I. – Sebestyen, A. (2006): Financial Deficits in the Health Services of the UK and Hungary. The Lancet 9593: 917.
-
Brodszky, V. – Baji, P. – Balogh, O. – Péntek, M. (2014): Budget Impact Analysis of Biosimilar Infliximab (CT-P13) for the Treatment of Rheumatoid Arthritis in Six Central and Eastern European Countries. The European Journal of Health Economics 15: 65–71.
-
Catanoso, M. – Pipitone, N. – Salvarani. C. (2012): Epidemiology of Psoriatic Arthritis. Reumatismo 64: 66–70.
-
Credit Suisse (2014): USD CHF Average Exchange Rate 2014. https://www.creditsuisse.com/media/production /pb/docs/unternehmen/kmugrossunternehmen/en/devisendurchschnittskurse- 2014.pdf, accessed 26 March 2016.
-
Dankó, D. – Frang, G. – Girbicz, N. – Molnár, M. (2011). Alternatívák a biohasonló gyógyszerek fenntartható közfinanszírozási rendszerére [Alternatives for Sustainable Public Financing of Biosimilars] http://www.generikusegyesulet.hu/contents/uploads/documents/document_ 1328444930_700.pdf, accessed 29 March 2016.
-
Daubenfeld, T. – Dassow, J. – Kessler, M. – Schulze, J. (2016): Understanding the Market Dynamics of Biosimilars. Journal of Business Chemistry 13: 33–46.
-
Dean, L. E. – Jones, G. T. – MacDonald, A. G. – Downham, C. – Sturrock, R. D. – Macfarlane, G. J. (2014): Global Prevalence of Ankylosing Spondylitis. Rheumatology 53: 650–657.
-
Dorner, T. – Strand, V. – Cornes, P. – Goncalves, J. – Gulacsi, L. – Kay, J. – Kvien, T. K. – Smolen, J. – Tanaka, Y. – Burmester, G. R. (2016): The Changing Landscape of Biosimilars in Rheumatology. Annals of the Rheumatic Diseases 75(6): 974–982.
-
EBE (2015): What Pricing and Reimbursement Policies to Use for off-Patent Biologicals? — Results from the EBE 2014 Biological Medicines Policy Survey. Generics and Biosimilars Initiative Journal 4: 17–24.
-
EGA (2016): Biosimilars Handbook http://www.medicinesforeurope.com/2016/02/19/biosimilars- handbook/, accessed 4 October 2016.
-
EMA (2016a): European Public Assessment Reports, http://www.ema.europa.eu/ema/index. jsp?curl=pages%2 Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124 &searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised &status=Withdrawn&status=Suspended&status=Refused&keyword=Enter+keywords&search Type=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeyw ordSearch=Submit, accessed 18 February 2016.
-
EMA (2016b): Q&A: Similar Biological Products — Biosimilar Medicines http://www.ema.europa. eu/ema/index. jsp?curl=pages/special_topics/document_listing/document_listing_000318.jsp, accessed 18 February 2016.
-
EMA (2016c): Medicines under Evaluation http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/document_listing/document_listing_000349.jsp&mid=WC0b01ac05805083eb, accessed 20 February 2016.
-
Emerton, D. A. (2013): Profitability in the Biosimilars Market, http://www.bioprocessintl.com/upstream-processing/upstream-contract-services/profitability-in-the-biosimilars-market-344001/, accessed 20 February 2016.
-
Emery, P. – Hawkins, T. (2015): Biosimilar Medicines in Rheumatology. http://www.pharmaceutical-journal.com/learning/learning-article/biosimilar-medicines-in-rheumatology/20200018. article, accessed 20 February 2016.
-
epgonline.org. (2015): Price Cutting of Biosimilar Infliximab Drugs in Norway-Hospira and Orion Oyj. http://www.epgonline.org/news/price-cutting-of-biosimilar-infliximab-drugs-in-norwayhospira. cfm, accessed 10 April 2016.
-
EUMUSC (2011): Musculoskeletal Health in Europe Report v5.0. http://www.eumusc.net/my UploadData/files/Musculoskeletal%20Health%20in%20Europe%20Report%20v5.pdf, accessed 20 February 2016.
-
Evaluate Pharma. (2015): EvaluatePharma World Preview 2015 — Outlook to 2020 http://www. evaluategroup. com/public/reports/EvaluatePharma-World-Preview-2015.aspx, accessed 20 February 2016.
-
Gulácsi, L. – Brodszky, V. – Baji, P. – Kim, H. – Kim, S. Y. – Cho, Y. Y. – Péntek, M. (2015): Biosimilars for the Management of Rheumatoid Arthritis: Economic Considerations. Expert Review of Clinical Immunology 11(S1): 43–52.
-
Gulácsi, L. – Rencz, F. – Péntek, M. – Brodszky, V. – Lopert, R. – Hevér, N. V. – Baji, P. (2014): Transferability of Results of Cost Utility Analyses for Biologicals in Inflammatory Conditions for Central and Eastern European Countries. The European Journal of Health Economics 15: 27–34.
-
Gulácsi, L. – Rencz, F. – Poór, G. – Szekanecz, Z. – Brodszky, V. – Baji, P. – Péntek, M. (2016): Patients’ Access to Biological Therapy in Chronic Inflammatory Conditions; per Capita GDP does not Explain the Intercountry Differences. Annals of the Rheumatic Diseases annrheumdis–2015–208741. doi:10.1136/annrheumdis-2015-208741
-
Hanova, P. – Pavelka, K. – Dostal, C. – Holcatova, I. – Pikhart, H. (2006): Epidemiology of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis and Gout in Two Regions of the Czech Republic in a Descriptive Population-Based Survey in 2002-2003. Clinical and Experimental Rheumatology 24: 499–507.
-
Hanova, P. – Pavelka, K. – Holcatova, I. – Pikhart, H. (2010): Incidence and Prevalence of Psoriatic Arthritis, Ankylosing Apondylitis, and Reactive Arthritis in the First Descriptive Population- Based Study in the Czech Republic. Scandinavian Journal of Rheumatology 39: 310–317.
-
Healthware Tanácsadó Kft. (2015): A gyógyszerfinanszírozási piac aktuális kérdései [Burning Issues of the Pharmaceutical Reimbursement Market], http://www.healthware.hu/files/newsletter /HW_Hirlevel_ 2015_julius.pdf, accessed 30 July 2016.
-
Hoffmann La Roche Ltd. (2014): Roche Annual Report, http://www.roche.com/investors/reporting/ar14_highlights.htm, accessed 26 March 2016.
-
Hornyák, L. – Nagy, Z. – Tálos, Z. – Endrei, D. – Ágoston, I. – Csákvári, T. – Boncz, I. (2014): A biohasonló gyógyszerek árversenyének tapasztalatai Magyarországon. [Experiences with Price Competition of Biosimilar Drugs in Hungary]. Acta Pharmaceutica Hungarica 2014(2): 1–5.
-
IMS Health (2015): The Impact of Biosimilar Competition, http://www. medicinesforeurope. com/2015/11/01/the-impact-of-biosimilar-competition/, accessed 20 February 2016.
-
Johnson & Johnson Ltd. (2014): Johnson & Johnson Annual Report, http://www.investor.jnj.com /secfiling. cfm?filingid=200406-15-4&cik=, accessed 26 March 2016.
-
Kiss, C. G. – Lövei, C. – Sütö, G. – Varjú, C. – Nagy, Z. – Füzesi, Z. – Illés, T. – Czirják, L. (2005): Prevalence of Rheumatoid Arthritis in the South-Transdanubian Region of Hungary Based on a Representative Survey of 10.000 Inhabitants. The Journal of Rheumatology 32: 1688–1690.
-
KSH (2016): 6.1.2. A lakónépesség korcsoport szerint, január 1. [6.1.2. Population by Age Groups 1st January], http://www. ksh.hu/docs/hun/xstadat/xstadat_eves/i_wdsd004b.html, accessed 26 March 2016.
-
Kobelt, G. – Kasteng, F. (2009): Access to Innovative Treatments in Rheumatoid Arthritis in Europe. A report prepared for the European Federation of Pharmaceutical Industry Associations (EFPIA) http://www.comparatorreports.se/Access%20to%20 RA%20Treatments%20 October %202009.pdf, accessed 27 March 2016.
-
Kobelt, G. – Sobocki, P. – Mulero, J. – Gratacos, J. – Pocovi, A. – Collantes–Estevez, E. (2008): The Burden of Ankylosing Spondylitis in Spain. Value in Health 11: 408–415.
-
Laki, J. – Mónok, G. – Pálosi, M. – Gajdácsi, J. Z. (2013): Economical Aspect of Biological Therapy in Inflammatory Conditions in Hungary. Expert Opinion on Biological Therapy 13: 327–337.
-
Lekander, I. – Borgström, F. – Lysholm, J. – van Vollenhoven, R. F. – Lindblad, S. – Geborek, P. – Kobelt, G. (2013): The Cost-Effectiveness of TNF-Inhibitors for the Treatment of Rheumatoid Arthritis in Swedish Clinical Practice. The European Journal of Health Economics 14(6): 863–873.
-
Mack, A. (2015): Norway. Biosimilars in Different Funding Systems. What Works? Generics and Biosimilars Initiative Journal 4: 90–92.
-
Magyar Államkincstár. (2014): TB Alapok Mérlege [Balance of Healthcare Funds], http://www. allamkincstar .gov.hu/hu/koltsegvetesi-informaciok /koltsegvetes_merleg_4/225/, accessed 27 March 2016.
-
Nisen, M. (2016): The Best Selling Prescription Drugs in the World Last Year. http://qz.com/349929/best-selling-drugs-in-the-world/, accessed 20 February 2016.
-
OEP (2016a): Gyógyszerforgalmi adatok: éves riport 2015 [Pharmaceutical Sales Data: annual report 2015], http://www.oep.hu/felso_menu/szakmai_oldalak/publikus_forgalmi_adatok/gyogyszer forgalmi_adatok, accessed: 30 July 2016.
-
OEP (2016b): teteles.oep.hu [itemized accounts webpage], http://teteles.oep.hu/, accessed 10 April 2016.
-
OEP (2016c): Közbeszerzési eljárások [Public Procurement Procedures] http://www.oep.hu/felso_menu/rolunk/kozerdeku_adatok/kozbeszerzesi _informaciok/kozbeszerzesi_eljarasok, accessed 27 March 2016.
-
Orlewska, E. – Ancuta, I. – Anic, B. – Codrenau, C. – Damjanov, N. – Djukic, P. – Ionescu, R. – Marinchev, L. – Nasonov, E. L. – Peets, T. – Praprotnik, S. – Rashkov, R. – Skoupa, J. – Tlustochowicz, W. – Tlustochowicz, M. – Tomsic, M. – Veldi, T. – Vojinovic, J. – Wiland, P. (2011): Access to Biologic Treatment for Rheumatoid Arthritis in Central and Eastern European (CEE) Countries. Medical Science Monitor 17: SR1–SR13.
-
Péntek, M. – Poór, G. – Wiland, P. – Olejárova, M. – Brzosko, M. – Codreanu, C. – Brodszky, N. – Gulácsi, L. (2014): Biological Therapy in Inflammatory Rheumatic Diseases: Issues in Central and Easter European Countries. The European Journal of Health Economics 15(S1): S35–S43.
-
Poór, G. (2015): Tízéves az arthritisek biológiai terápiás ellátása Magyarországon [The Biological Therapy of Arthritides is 10 Years Old in Hungary]. Hungarian Rheumatology 56: 199–207.
-
Putrik, P. – Ramiro, S. – Kvien, T. – Sokka, T. – Pavlova, M. – Uhlig, T. – Boonen, A. (2014): Inequities in Access to Biologic and Synthetic DMARDs across 46 European Countries. Annals of the Rheumatic Diseases 73: 198–206.
-
PMLiVE (2014): Top 50 Pharmaceutical Products by Global Sales, http://www.pmlive.com/top_ pharma _list/Top_50 _pharmaceutical_products_by_global_sales, accessed 7 April 2016.
-
Rittenberg, L. – Tregarthen, T. (2008): Principles of Microeconomics. Nyack: Flat World Knowledge.
-
Reveille, J. D. – Ximenes, A. – Ward, M. M. (2012): Economic Considerations of the Treatment of Ankylosing Spondylitis. American Journal of Medical Science 343: 371–374.
-
Stanton, D. (2016): Biosimilar Discounts and Switching will Wipe-out J&J’s Remicade in Norway Says Regulator, http://www.biopharma-reporter.com/Markets-Regulations/Biosimilardiscounts- will-wipe-out-Janssen-s-Remicade-sales-in-Norway, accessed 17 April 2016.
-
Statista (2016a): Bristol-Myers Squibb Top-Products Revenues 2008-2015. Statistic http://www. statista.com /statistics/266585/bristol-myers-squibbs-top-products-based-on-revenue/, accessed 26 March 2016.
-
Statista (2016b): EUR USD Annual Average Exchange Rate 1999-2015. Statistic, http://www.statista.com /statistics/412794/euro-to-u-s-dollar-annual-average-exchange-rate/, accessed 26 March 2016.
-
Thimmaraju, P. K. – Rakshambikai, R. – Farista, R. – Juluru, K. (2015): Legislations on Biosimilar Interchangeability in the US and EU — Developments Far from Visibility, http://www.gabionline. net/Sponsored-Articles/Legislations-on-biosimilar-interchangeability-in-the-US-and-EUdevelopments- far-from-visibility, accessed 10 April 2016.
-
WHO (2011): International Nonproprietary Names (INN) for Biological and Biotechnological Substances (A Review). Geneva: WHO.
-
Zeidler, J. – Mittendorf, T. – Müller, R. – von Kempis, J. (2012). Biologic TNF Inhibiting Agents for Treatment of Inflammatory Rheumatic Diseases: Dosing Patterns and Related Costs in Switzerland from a Payers Perspective. Health Economics Review 2(1): 1–8.
Editor-in-chief: Balázs SZENT-IVÁNYI
Co-Editors:
- Péter MARTON (Corvinus University, Budapest)
- István KÓNYA (Corvinus University, Budapest)
- László SAJTOS (The University of Auckland)
- Gábor VIRÁG (University of Toronto)
Associate Editors:
- Tamás BOKOR (Corvinus University, Budapest)
- Sándor BOZÓKI (Corvinus University Budapest)
- Bronwyn HOWELL (Victoria University of Wellington)
- Hintea CALIN (Babeş-Bolyai University)
- Christian EWERHART (University of Zürich)
- Clemens PUPPE (Karlsruhe Institute of Technology)
- Zsolt DARVAS (Bruegel)
- Szabina FODOR (Corvinus University Budapest)
- Sándor GALLAI (Corvinus University Budapest)
- László GULÁCSI (Óbuda University)
- Dóra GYŐRFFY (Corvinus University Budapest)
- György HAJNAL (Corvinus University Budapest)
- Krisztina KOLOS (Corvinus University Budapest)
- Alexandra KÖVES (Corvinus University Budapest)
- Lacina LUBOR (Mendel University in Brno)
- Péter MEDVEGYEV (Corvinus University Budapest)
- Miroslava RAJČÁNIOVÁ (Slovak University of Agriculture)
- Ariel MITEV (Corvinus University Budapest)
- Éva PERPÉK (Corvinus University Budapest)
- Petrus H. POTGIETER (University of South Africa)
- Sergei IZMALKOV (MIT Economics)
- Anita SZŰCS (Corvinus University Budapest)
- László TRAUTMANN (Corvinus University Budapest)
- Trenton G. SMITH (University of Otago)
- György WALTER (Corvinus University Budapest)
- Zoltán CSEDŐ (Corvinus University Budapest)
- Zoltán LŐRINCZI (Ministry of Human Capacities)
Society and Economy
Institute: Corvinus University of Budapest
Address: Fővám tér 8. H-1093 Budapest, Hungary
Phone: (36 1) 482 5406
E-mail: balazs.szentivanyi@uni-corvinus.hu
Indexing and Abstracting Services:
- CABELLS Journalytics
- DOAJ
- International Bibliographies IBZ and IBR
- International Political Science Abstracts
- JSTOR
- SCOPUS
- RePEc
- Referativnyi Zhurnal
| 2023 | |
|---|---|
| Scopus | |
| CiteScore | 1.5 |
| CiteScore rank | Q2 (Sociology and Political Science) |
| SNIP | 0.496 |
| Scimago | |
| SJR index | 0.243 |
| SJR Q rank | Q3 |
| Society and Economy | |
|---|---|
| Publication Model | Gold Open Access |
| Submission Fee | none |
| Article Processing Charge | 900 EUR/article with enough waivers |
| Regional discounts on country of the funding agency | World Bank Lower-middle-income economies: 50% World Bank Low-income economies: 100% |
| Further Discounts | Sufficient number of full waiver available. Editorial Board / Advisory Board members: 50% Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100% |
| Subscription Information | Gold Open Access |
| Society and Economy | |
|---|---|
| Language | English |
| Size | B5 |
| Year of Foundation |
1972 |
| Volumes per Year |
1 |
| Issues per Year |
4 |
| Founder | Budapesti Corvinus Egyetem |
| Founder's Address |
H-1093 Budapest, Hungary Fővám tér 8. |
| Publisher | Akadémiai Kiadó |
| Publisher's Address |
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245. |
| Responsible Publisher |
Chief Executive Officer, Akadémiai Kiadó |
| ISSN | 1588-9726 (Print) |
| ISSN | 1588-970X (Online) |
Monthly Content Usage
| Abstract Views | Full Text Views | PDF Downloads | |
|---|---|---|---|
| Oct 2024 | 133 | 0 | 0 |
| Nov 2024 | 28 | 1 | 1 |
| Dec 2024 | 11 | 0 | 0 |
| Jan 2025 | 45 | 0 | 0 |
| Feb 2025 | 48 | 0 | 0 |
| Mar 2025 | 27 | 0 | 0 |
| Apr 2025 | 0 | 0 | 0 |
Author:
Author:
Author:
Sustainability as a driver for corporate economic success
Consequences for the development of sustainability management control
Author:
Author:
Author:
Copyright Akadémiai Kiadó AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.
Powered by PubFactory